암 부담 및 역학 분석 : 성별(2026-2035년)

Cancer remains one of the leading causes of morbidity and mortality worldwide, with approximately 20 million new cancer cases and 9.7 million cancer-related deaths reported globally in 2022. Epidemiological evidence consistently demonstrates significant differences in cancer incidence, mortality, risk factors, disease progression, treatment outcomes, and survival rates between males and females. These gender-based variations have become increasingly important for healthcare providers, pharmaceutical companies, policymakers, and public health organizations seeking to develop more targeted cancer prevention and treatment strategies.

Gender-specific cancer epidemiology analysis examines disease burden across male and female populations, providing critical insights into cancer prevalence, incidence, mortality, survival rates, risk exposures, healthcare utilization, and future patient population trends. Such analyses support evidence-based decision-making in oncology research, healthcare resource allocation, clinical development, and public health policy formulation.

Market Drivers

Rising Global Cancer Burden

One of the primary drivers of market growth is the continued increase in global cancer incidence. Recent estimates indicate that nearly 20 million new cancer cases were diagnosed worldwide in 2022, with cancer burden expected to rise significantly over the coming decades due to population growth and aging demographics. Projections suggest global cancer cases could reach approximately 35 million annually by 2050.

The increasing disease burden is creating strong demand for comprehensive epidemiological intelligence that can identify gender-specific trends and support healthcare planning.

Growing Focus on Precision Public Health

Healthcare systems are increasingly moving toward precision medicine and personalized healthcare approaches. Understanding how cancer affects men and women differently is becoming critical for developing targeted prevention strategies, screening programs, and treatment interventions.

Gender-based epidemiological analysis helps identify unique risk profiles, disease patterns, and healthcare needs within different population groups.

Significant Gender Differences in Cancer Epidemiology

Research demonstrates that cancer incidence and mortality rates differ substantially between men and women. In 2022, approximately 10.3 million cancer cases occurred among men compared with 9.7 million among women globally. Age-standardized incidence rates were also higher among men than women. Recent Global Burden of Disease analyses further indicate that cancer incidence and mortality rates remain significantly higher in males than females worldwide.

These differences are driving demand for specialized epidemiological studies focused on gender-specific disease burden assessment.

Expansion of Cancer Registries and Real-World Data Sources

The increasing availability of electronic health records, cancer registries, genomic databases, mortality records, insurance claims databases, and population health platforms is improving access to large-scale epidemiological data.

These resources enable more detailed analysis of gender-based differences in cancer occurrence, treatment outcomes, and long-term survival patterns.

Market Restraints

Variability in Data Quality Across Regions

Differences in healthcare infrastructure, cancer registry coverage, diagnostic capabilities, and reporting standards can create inconsistencies in epidemiological datasets across countries and regions.

These variations may affect the accuracy and comparability of gender-specific cancer burden estimates.

Underdiagnosis and Healthcare Access Disparities

In many developing regions, limited access to cancer screening, diagnostic services, and healthcare infrastructure can result in underreporting of cancer cases.

Gender-related disparities in healthcare access may further complicate epidemiological assessments and disease burden analyses.

Complex Interaction of Biological and Social Factors

Cancer burden differences between men and women are influenced by a combination of biological, hormonal, genetic, behavioral, occupational, environmental, and socioeconomic factors. Understanding the interaction of these variables requires sophisticated epidemiological modeling and analysis.

Technology and Segment Insights

The global cancer burden and epidemiology analysis by gender market can be segmented by gender, cancer type, data source, application, end user, and geography.

By gender, the market includes male and female populations. Men generally experience higher overall cancer incidence and mortality rates compared to women, while women face substantial burdens from gender-specific cancers such as breast, cervical, ovarian, and uterine cancers. Studies indicate that cancer incidence and mortality rates in men are approximately 20-30% higher than in women across many regions.

By cancer type, the market includes lung cancer, breast cancer, prostate cancer, colorectal cancer, liver cancer, stomach cancer, cervical cancer, ovarian cancer, pancreatic cancer, hematological malignancies, and other cancers. Lung cancer remains the leading cause of cancer mortality globally and is particularly prevalent among men, while breast cancer is the most commonly diagnosed cancer among women worldwide.

By data source, the market includes cancer registries, hospital databases, electronic health records, insurance claims databases, mortality databases, genomic databases, public health surveillance systems, and national health surveys. Cancer registries continue to represent one of the most important sources of epidemiological intelligence.

By application, the market includes incidence analysis, prevalence assessment, mortality analysis, survival analysis, patient population forecasting, healthcare planning, public health policy development, clinical research support, and pharmaceutical market assessment. Disease burden forecasting and healthcare resource planning remain major application areas.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, government agencies, public health organizations, contract research organizations, and healthcare consulting firms. Government agencies and public health organizations account for a significant share of demand due to their role in population health management and disease surveillance.

Technological advancements are transforming epidemiological analysis through artificial intelligence, machine learning, predictive analytics, real-world evidence platforms, population health modeling, and advanced statistical methodologies. These technologies enable more accurate forecasting of gender-specific cancer trends and support evidence-based healthcare decision-making.

The integration of genomic information, molecular profiling data, lifestyle factors, environmental exposure metrics, and healthcare utilization records is creating increasingly sophisticated epidemiological models that can identify emerging disease patterns and support precision oncology initiatives.

Geographically, North America dominates the market due to advanced healthcare infrastructure, comprehensive cancer registries, strong oncology research capabilities, and widespread adoption of healthcare analytics technologies. Europe maintains a significant market position supported by established public health systems and collaborative cancer surveillance programs. Asia-Pacific is expected to experience the fastest growth due to rising cancer incidence, expanding healthcare infrastructure, growing research investments, and large patient populations in countries such as China, India, Japan, and South Korea. Latin America and the Middle East & Africa are also strengthening cancer surveillance capabilities and expanding epidemiological research initiatives.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, academic institutions, cancer research centers, public health agencies, contract research organizations, and healthcare intelligence companies. Market participants are investing in advanced analytics platforms, real-world evidence capabilities, predictive modeling technologies, and integrated population health solutions.

Strategic collaborations among pharmaceutical companies, healthcare providers, academic institutions, government agencies, and technology firms are becoming increasingly common as stakeholders seek to improve cancer surveillance, patient population forecasting, and healthcare planning capabilities.

Organizations are also expanding investments in precision medicine, gender-based oncology research, and advanced epidemiological intelligence solutions to address the growing complexity of global cancer management.

Conclusion

The global cancer burden and epidemiology analysis by gender market is poised for strong growth through 2031, supported by rising cancer incidence, increasing recognition of gender-specific disease patterns, expanding healthcare data infrastructure, and growing demand for personalized healthcare strategies. Significant differences in cancer incidence, mortality, risk factors, and treatment outcomes between men and women are creating greater demand for detailed epidemiological intelligence. While challenges related to data quality, healthcare disparities, and analytical complexity remain, advances in artificial intelligence, real-world evidence analytics, and population health technologies are expected to significantly enhance gender-specific cancer surveillance and forecasting capabilities. As healthcare systems increasingly focus on precision public health and personalized oncology, gender-based epidemiological analysis will play an increasingly important role in supporting effective healthcare decision-making and improving patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Comprehensive assessment of cancer incidence, prevalence, mortality, survival, and patient populations by gender.
• Competitive Landscape: Understand emerging epidemiological trends, gender-specific disease patterns, and research developments.
• Market Drivers and Future Trends: Evaluate key growth factors and technological advancements shaping oncology epidemiology.
• Actionable Recommendations: Support healthcare planning, policy development, prevention strategies, and investment decisions.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, healthcare providers, public health agencies, academic institutions, consultants, and investors.

What Businesses Use Our Reports For

Patient population forecasting, disease burden assessment, oncology market evaluation, healthcare planning, clinical research support, public health policy development, investment analysis, epidemiological intelligence, and competitive benchmarking.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Global, regional, and country-level incidence, prevalence, mortality, survival, and patient population analysis by gender
• Gender-specific cancer trends, risk factor assessments, and disease burden forecasting
• Healthcare policy evaluation, oncology planning insights, and population health analysis
• Competitive intelligence, research developments, and future market opportunity assessment.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
  • 1.1.1 Definition of Cancer Epidemiology by Gender
  • 1.1.2 Scope of the Report
  • 1.1.3 Key Epidemiological Insights
  • 1.1.4 Key Market Trends
  • 1.1.5 Gender-Based Burden Overview
  • 1.1.6 Screening and Diagnostic Trends
  • 1.1.7 Treatment Access Trends
  • 1.1.8 Regional Market Highlights
  • 1.1.9 Competitive Landscape Snapshot
  • 1.1.10 Future Growth Outlook
• 1.2 Research Assumptions and Limitations
  • 1.2.1 Inclusion Criteria
  • 1.2.2 Exclusion Criteria
  • 1.2.3 Forecasting Methodology Assumptions

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Cancer Epidemiology
  • 2.1.1 Global Cancer Burden by Gender
  • 2.1.2 Biological and Hormonal Influences on Cancer Incidence
  • 2.1.3 Gender Disparities in Cancer Mortality
  • 2.1.4 Gender-Based Differences in Cancer Screening
• 2.2 Global Epidemiology Overview
  • 2.2.1 Incidence Analysis by Gender
  • 2.2.2 Prevalence Analysis by Gender
  • 2.2.3 Mortality Analysis by Gender
  • 2.2.4 Survival Rate Trends by Gender
  • 2.2.5 Disability-Adjusted Life Years (DALYs) Analysis
• 2.3 Male Cancer Epidemiology
  • 2.3.1 Prostate Cancer
  • 2.3.2 Lung Cancer in Males
  • 2.3.3 Colorectal Cancer in Males
  • 2.3.4 Liver Cancer in Males
  • 2.3.5 Bladder Cancer in Males
  • 2.3.6 Gastric Cancer in Males
• 2.4 Female Cancer Epidemiology
  • 2.4.1 Breast Cancer
  • 2.4.2 Cervical Cancer
  • 2.4.3 Ovarian Cancer
  • 2.4.4 Endometrial Cancer
  • 2.4.5 Lung Cancer in Females
  • 2.4.6 Colorectal Cancer in Females
• 2.5 Shared High-Burden Cancers by Gender
  • 2.5.1 Lung Cancer
  • 2.5.2 Colorectal Cancer
  • 2.5.3 Hematologic Malignancies
  • 2.5.4 Melanoma
  • 2.5.5 Pancreatic Cancer
• 2.6 Epidemiology by Age Group
  • 2.6.1 Pediatric Population
  • 2.6.2 Adult Population
  • 2.6.3 Geriatric Population
• 2.7 Epidemiology by Cancer Stage
  • 2.7.1 Early-Stage Disease
  • 2.7.2 Locally Advanced Disease
  • 2.7.3 Metastatic Disease
• 2.8 Risk Factor Assessment
  • 2.8.1 Tobacco Use
  • 2.8.2 Alcohol Consumption
  • 2.8.3 Obesity and Metabolic Disorders
  • 2.8.4 Occupational Exposure
  • 2.8.5 Viral Infections
  • 2.8.6 Genetic Predisposition
  • 2.8.7 Environmental Exposure
• 2.9 Screening and Early Detection Trends
  • 2.9.1 Mammography Screening
  • 2.9.2 Pap Smear and HPV Testing
  • 2.9.3 PSA Testing
  • 2.9.4 Colonoscopy Screening
  • 2.9.5 Low-Dose CT Screening for Lung Cancer

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Global Cancer Incidence
  • 3.1.2 Growing Awareness of Gender-Specific Oncology
  • 3.1.3 Expansion of Precision Medicine
  • 3.1.4 Increasing Cancer Screening Programs
  • 3.1.5 Growth in Immuno-Oncology Adoption
• 3.2 Market Restraints
  • 3.2.1 High Cost of Cancer Treatment
  • 3.2.2 Limited Access in Low- and Middle-Income Regions
  • 3.2.3 Late Diagnosis Challenges
  • 3.2.4 Reimbursement Limitations
• 3.3 Market Opportunities
  • 3.3.1 Biomarker-Driven Therapeutics
  • 3.3.2 AI-Based Cancer Diagnostics
  • 3.3.3 Expansion of Companion Diagnostics
  • 3.3.4 Gender-Specific Preventive Oncology
• 3.4 Market Challenges
  • 3.4.1 Clinical Trial Recruitment Diversity
  • 3.4.2 Variability in Healthcare Infrastructure
  • 3.4.3 Regulatory Delays
  • 3.4.4 Data Integration Challenges

4. Commercial & Market Access

• 4.1 Reimbursement Landscape
  • 4.1.1 Public Reimbursement Models
  • 4.1.2 Private Insurance Coverage
  • 4.1.3 Value-Based Oncology Pricing
  • 4.1.4 Access Barriers by Gender
• 4.2 Pricing Analysis
  • 4.2.1 Branded Oncology Drug Pricing
  • 4.2.2 Biosimilar Pricing Trends
  • 4.2.3 Regional Pricing Variability
• 4.3 Market Access Strategies
  • 4.3.1 Patient Assistance Programs
  • 4.3.2 Early Access Programs
  • 4.3.3 Health Technology Assessment (HTA) Impact

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends
  • 5.1.1 Precision Oncology
  • 5.1.2 Cell and Gene Therapy
  • 5.1.3 Antibody-Drug Conjugates (ADCs)
  • 5.1.4 Radiopharmaceuticals
  • 5.1.5 Liquid Biopsy Technologies
• 5.2 Pipeline Analysis by Development Phase
  • 5.2.1 Phase I Pipeline Candidates
  • 5.2.2 Phase II Pipeline Candidates
  • 5.2.3 Phase III Pipeline Candidates
• 5.3 Pipeline Analysis by Modality
  • 5.3.1 Monoclonal Antibodies
  • 5.3.2 Small Molecules
  • 5.3.3 Cell Therapies
  • 5.3.4 Cancer Vaccines
  • 5.3.5 Gene Therapies
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 PD-1/PD-L1 Inhibitors
  • 5.4.2 CTLA-4 Inhibitors
  • 5.4.3 HER2-Targeted Therapies
  • 5.4.4 PARP Inhibitors
  • 5.4.5 CDK4/6 Inhibitors
  • 5.4.6 EGFR Inhibitors

6. Treatment Landscape

• 6.1 Standard of Care Overview
  • 6.1.1 Surgery
  • 6.1.2 Radiation Therapy
  • 6.1.3 Chemotherapy
  • 6.1.4 Immunotherapy
  • 6.1.5 Hormonal Therapy
  • 6.1.6 Targeted Therapy
• 6.2 Approved Drug Landscape
  • 6.2.1 Immune Checkpoint Inhibitors
  • 6.2.2 Targeted Oncology Therapies
  • 6.2.3 Hormonal Oncology Therapies
  • 6.2.4 Biosimilars in Oncology
• 6.3 Treatment Guidelines Landscape
  • 6.3.1 NCCN Guidelines
  • 6.3.2 ESMO Guidelines
  • 6.3.3 ASCO Guidelines
  • 6.3.4 National Guideline Variability
• 6.4 Gender-Specific Treatment Trends
  • 6.4.1 Hormonal Influence on Therapy Selection
  • 6.4.2 Gender-Based Clinical Outcomes
  • 6.4.3 Adverse Event Profile Differences

7. Cancer Epidemiology by Gender Report Size & Forecast

• 7.1 Global Market Overview
  • 7.1.1 Historical Market Size Analysis
  • 7.1.2 Current Market Assessment
  • 7.1.3 Forecast Market Size Analysis
• 7.2 Market Forecast by Gender
  • 7.2.1 Male Oncology Market
  • 7.2.2 Female Oncology Market
• 7.3 Market Forecast by Cancer Type
• 7.4 Market Forecast by Therapy Type

8. Cancer Epidemiology by Gender Report Segmentation

• 8.1 By Cancer Type
  • 8.1.1 Breast Cancer
  • 8.1.2 Prostate Cancer
  • 8.1.3 Lung Cancer
  • 8.1.4 Colorectal Cancer
  • 8.1.5 Cervical Cancer
  • 8.1.6 Ovarian Cancer
  • 8.1.7 Liver Cancer
  • 8.1.8 Hematologic Malignancies
• 8.2 By Therapy Type
  • 8.2.1 Chemotherapy
  • 8.2.2 Immunotherapy
  • 8.2.3 Targeted Therapy
  • 8.2.4 Hormonal Therapy
  • 8.2.5 Cell Therapy
• 8.3 By Drug Class
  • 8.3.1 PD-1/PD-L1 Inhibitors
  • 8.3.2 CTLA-4 Inhibitors
  • 8.3.3 PARP Inhibitors
  • 8.3.4 CDK4/6 Inhibitors
  • 8.3.5 Others
• 8.4 By Gender
  • 8.4.1 Male
  • 8.4.2 Female
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Cancer Centers
  • 8.5.3 Ambulatory Surgical Centers
  • 8.5.4 Academic and Research Institutes
• 8.6 By Distribution Channel
  • 8.6.1 Hospital Pharmacies
  • 8.6.2 Retail Pharmacies & Specialty Pharmacies
  • 8.6.4 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Cancer Epidemiology by Gender
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Landscape
  • 10.1.5 Key Companies and Product Presence
• 10.2 Canada
  • 10.2.1 Market Size
  • 10.2.2 Cancer Epidemiology by Gender
  • 10.2.3 Regulatory Framework
  • 10.2.4 Reimbursement Landscape
  • 10.2.5 Key Companies and Product Presence
• 10.3 Germany
  • 10.3.1 Market Size
  • 10.3.2 Cancer Epidemiology by Gender
  • 10.3.3 Regulatory Framework
  • 10.3.4 Reimbursement Landscape
  • 10.3.5 Key Companies and Product Presence
• 10.4 United Kingdom
  • 10.4.1 Market Size
  • 10.4.2 Cancer Epidemiology by Gender
  • 10.4.3 Regulatory Framework
  • 10.4.4 Reimbursement Landscape
  • 10.4.5 Key Companies and Product Presence
• 10.5 France
  • 10.5.1 Market Size
  • 10.5.2 Cancer Epidemiology by Gender
  • 10.5.3 Regulatory Framework
  • 10.5.4 Reimbursement Landscape
  • 10.5.5 Key Companies and Product Presence
• 10.6 Italy
  • 10.6.1 Market Size
  • 10.6.2 Cancer Epidemiology by Gender
  • 10.6.3 Regulatory Framework
  • 10.6.4 Reimbursement Landscape
  • 10.6.5 Key Companies and Product Presence
• 10.7 Spain
  • 10.7.1 Market Size
  • 10.7.2 Cancer Epidemiology by Gender
  • 10.7.3 Regulatory Framework
  • 10.7.4 Reimbursement Landscape
  • 10.7.5 Key Companies and Product Presence
• 10.8 China
  • 10.8.1 Market Size
  • 10.8.2 Cancer Epidemiology by Gender
  • 10.8.3 Regulatory Framework
  • 10.8.4 Reimbursement Landscape
  • 10.8.5 Key Companies and Product Presence
• 10.9 Japan
  • 10.9.1 Market Size
  • 10.9.2 Cancer Epidemiology by Gender
  • 10.9.3 Regulatory Framework
  • 10.9.4 Reimbursement Landscape
  • 10.9.5 Key Companies and Product Presence
• 10.10 India
  • 10.10.1 Market Size
  • 10.10.2 Cancer Epidemiology by Gender
  • 10.10.3 Regulatory Framework
  • 10.10.4 Reimbursement Landscape
  • 10.10.5 Key Companies and Product Presence
• 10.11 South Korea
  • 10.11.1 Market Size
  • 10.11.2 Cancer Epidemiology by Gender
  • 10.11.3 Regulatory Framework
  • 10.11.4 Reimbursement Landscape
  • 10.11.5 Key Companies and Product Presence
• 10.12 Australia
  • 10.12.1 Market Size
  • 10.12.2 Cancer Epidemiology by Gender
  • 10.12.3 Regulatory Framework
  • 10.12.4 Reimbursement Landscape
  • 10.12.5 Key Companies and Product Presence
• 10.13 Brazil
  • 10.13.1 Market Size
  • 10.13.2 Cancer Epidemiology by Gender
  • 10.13.3 Regulatory Framework
  • 10.13.4 Reimbursement Landscape
  • 10.13.5 Key Companies and Product Presence
• 10.14 Mexico
  • 10.14.1 Market Size
  • 10.14.2 Cancer Epidemiology by Gender
  • 10.14.3 Regulatory Framework
  • 10.14.4 Reimbursement Landscape
  • 10.14.5 Key Companies and Product Presence
• 10.15 Saudi Arabia
  • 10.15.1 Market Size
  • 10.15.2 Cancer Epidemiology by Gender
  • 10.15.3 Regulatory Framework
  • 10.15.4 Reimbursement Landscape
  • 10.15.5 Key Companies and Product Presence
• 10.16 South Africa
  • 10.16.1 Market Size
  • 10.16.2 Cancer Epidemiology by Gender
  • 10.16.3 Regulatory Framework
  • 10.16.4 Reimbursement Landscape
  • 10.16.5 Key Companies and Product Presence

11. Regulatory & Policy Landscape

• 11.1 United States Regulatory Framework
  • 11.1.1 FDA Oncology Drug Approval Pathways
  • 11.1.2 Breakthrough Therapy and Accelerated Approval
• 11.2 Europe Regulatory Framework
  • 11.2.1 EMA Oncology Drug Approval Process
  • 11.2.2 EU HTA and MDR Overview
• 11.3 Japan Regulatory Framework
  • 11.3.1 PMDA Oncology Review Process
  • 11.3.2 Sakigake Designation
• 11.4 India Regulatory Framework
  • 11.4.1 CDSCO Oncology Product Approval
  • 11.4.2 Pricing and Access Policies
• 11.5 China Regulatory Framework
  • 11.5.1 NMPA Oncology Approval Process
  • 11.5.2 NRDL Reimbursement Inclusion
• 11.6 Clinical Trial and Pharmacovigilance Landscape
  • 11.6.1 Oncology Clinical Trial Governance
  • 11.6.2 Real-World Evidence Integration
  • 11.6.3 Post-Marketing Surveillance

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Strategic Collaborations and Partnerships
• 12.4 Mergers and Acquisitions
• 12.5 Licensing and Co-Development Agreements
• 12.6 New Product Launches
• 12.7 Clinical Trial Activity Analysis
• 12.8 Patent Landscape Analysis

13. Company Profiles

• 13.1 Roche Holding
  • 13.1.1 Oncology Portfolio Overview
  • 13.1.2 Approved Products
    • 13.1.2.1 Herceptin (trastuzumab)
    • 13.1.2.2 Avastin (bevacizumab)
    • 13.1.2.3 Tecentriq (atezolizumab)
  • 13.1.3 Key Indications
  • 13.1.4 Verified Pipeline Candidates
• 13.2 Merck & Co.
  • 13.2.1 Oncology Portfolio Overview
  • 13.2.2 Approved Products
    • 13.2.2.1 Keytruda (pembrolizumab)
  • 13.2.3 Key Indications
  • 13.2.4 Verified Pipeline Candidates
• 13.3 Bristol Myers Squibb
  • 13.3.1 Oncology Portfolio Overview
  • 13.3.2 Approved Products
    • 13.3.2.1 Opdivo (nivolumab)
    • 13.3.2.2 Yervoy (ipilimumab)
  • 13.3.3 Key Indications
  • 13.3.4 Verified Pipeline Candidates
• 13.4 AstraZeneca
  • 13.4.1 Oncology Portfolio Overview
  • 13.4.2 Approved Products
    • 13.4.2.1 Tagrisso (osimertinib)
    • 13.4.2.2 Lynparza (olaparib)
  • 13.4.3 Key Indications
  • 13.4.4 Verified Pipeline Candidates
• 13.5 Pfizer
  • 13.5.1 Oncology Portfolio Overview
  • 13.5.2 Approved Products
    • 13.5.2.1 Ibrance (palbociclib)
    • 13.5.2.2 Xtandi (enzalutamide)
  • 13.5.3 Key Indications
  • 13.5.4 Verified Pipeline Candidates
• 13.6 Novartis
  • 13.6.1 Oncology Portfolio Overview
  • 13.6.2 Approved Products
    • 13.6.2.1 Kisqali (ribociclib)
    • 13.6.2.2 Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
  • 13.6.3 Key Indications
  • 13.6.4 Verified Pipeline Candidates
• 13.7 Johnson & Johnson
  • 13.7.1 Oncology Portfolio Overview
  • 13.7.2 Approved Products
    • 13.7.2.1 Darzalex (daratumumab)
    • 13.7.2.2 Erleada (apalutamide)
  • 13.7.3 Key Indications
  • 13.7.4 Verified Pipeline Candidates
• 13.8 Eli Lilly and Company
  • 13.8.1 Oncology Portfolio Overview
  • 13.8.2 Approved Products
    • 13.8.2.1 Verzenio (abemaciclib)
    • 13.8.2.2 Retevmo (selpercatinib)
  • 13.8.3 Key Indications
  • 13.8.4 Verified Pipeline Candidates
• 13.9 GSK
  • 13.9.1 Oncology Portfolio Overview
  • 13.9.2 Approved Products
    • 13.9.2.1 Jemperli (dostarlimab)
    • 13.9.2.2 Zejula (niraparib)
  • 13.9.3 Key Indications
  • 13.9.4 Verified Pipeline Candidates
• 13.10 Amgen
  • 13.10.1 Oncology Portfolio Overview
  • 13.10.2 Approved Products
    • 13.10.2.1 Blincyto (blinatumomab)
    • 13.10.2.2 Lumakras (sotorasib)
  • 13.10.3 Key Indications
  • 13.10.4 Verified Pipeline Candidates

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Therapeutic Technologies
• 14.3 Gender-Specific Precision Oncology Outlook
• 14.4 AI and Digital Oncology Integration
• 14.5 Future Competitive Landscape
• 14.6 Long-Term Market Forecast

15. Methodology

• 15.1 Research Methodology
  • 15.1.1 Primary Research
  • 15.1.2 Secondary Research
  • 15.1.3 Data Validation
• 15.2 Market Estimation Techniques
  • 15.2.1 Top-Down Approach
  • 15.2.2 Bottom-Up Approach
  • 15.2.3 Forecast Modeling
• 15.3 Data Sources
  • 15.3.1 Regulatory Databases
  • 15.3.2 Company Annual Reports
  • 15.3.3 Clinical Trial Registries
  • 15.3.4 Peer-Reviewed Journals
  • 15.3.5 Healthcare Databases and Cancer Registries